Mr. James Howard-Tripp reports

STAGEZERO ANNOUNCES LISTING ON THE NEX EXCHANGE

Stagezero Life Sciences Ltd.'s application for listing on the NEX has been approved and its stock will be listed effective at the opening on Aug. 15, 2025, under the symbol SZLS.H, but the company remain subject to a trading suspension under the failure-to-file cease trade order (FFCTO).

The FFCTO was issued by the Ontario Securities Commission on April 8, 2024, against the company for failing to file its audited annual financial statements and associated filings for the year ended Dec. 31, 2023.

As of Aug. , 2025, the company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the company will change from SZLS to SZLS.H. There is no change in its Cusip number and no consolidation of capital.

The company will delist from trading on the Toronto Stock Exchange effective at the close on Thursday, Aug. 14, 2025.

The NEX is a separate board of the TSX Venture Exchange. The NEX offers its listed companies support and visibility provided by a listing and trading environment tailored to their needs specifically while they are restructuring or financing prior to reactivating their full business. Upon reactivation, the company has the option of applying to list on the Toronto Stock Exchange or the TSX Venture Exchange.

Moving to the NEX offers the following benefits to shareholders and the company:

• Continued trading within the prestigious TMX Group of stock exchanges. Trading on NEX takes place on the same fully electronic system as TSX-V and is governed by identical trading rules;
• Streamlined filing obligations, allowing more time for company to focus on reactivation. Disclosure obligations remain the same;
• An ability to raise capital with terms better suited to the company's current growth requirements;
• Lower listing costs.

The company is pursuing financing opportunities to raise sufficient funds to pay the significant, outstanding fees to the auditor and, as a result, allow the company to return to being compliant with the OSC filing requirements. Additionally, a financing will allow the company to scale and take full advantage of the partner opportunities it has secured, returning it to anticipated significant revenue generation. The company is working with the OSC, TSX and NEX to effect the listing and financing permissions.

"We are pleased to have been accepted on the NEX. We believe the exchange supports the company at this particular growth stage. We continue to work on the financing and the NEX listing is a positive step closer to concluding that," said James Howard-Tripp, chairman and chief executive officer of Stagezero Life Sciences.

The company has spent the last 18 months diligently working to reduce overhead, streamline operations and build partnerships that will strengthen the revenue funnel. A lack of financing has significantly impacted and delayed the company's growth. That said, the company now has a very streamlined operation, and is scaling in the partnered opportunities with Aristotle, AVRT and the CareOncology Protocol.

As previously stated, the company intends to use the proceeds of the proposed financing to: (i) pay fees to its current and former auditors, accountants and other service providers, as well as audit, accounting, legal and filing fees to be incurred in preparing and filing all outstanding documents; (ii) fulfill its operational and contractual commitments; and (iii) satisfy its operating expenses to ensure the continuity of the company's business during such time. The company reasonably believes that the proceeds from the proposed financing will be sufficient to bring its continuous disclosure obligations up to date and pay all related outstanding fees and provide it with sufficient working capital to meet its obligations and continue its business during such period.

About Stagezero Life Sciences Ltd.

Stagezero is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol), as well as help patients reduce the risk of developing late-stage disease (AVRT).

The company's next-generation test, Aristotle, is the first-ever mRNA multicancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types, and is built on the company's patented technology platform, the Sentinel Principle. The Sentinel Principle has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy.

Aristotle, as well as additional cancer diagnostics, are processed at the company's clinical laboratory, Stagezero Life Sciences Inc. in Richmond, Va.

We seek Safe Harbor.